China Resources Jiangzhong Pharmaceutical (600750.SS) Earnings Analysis

China Resources Jiangzhong Pharmaceutical (600750.SS) next reports earnings on 2026-08-22, consensus EPS 0.3815 CNY. Last quarter (2026-04-24) it missed with EPS 0.4466 CNY vs 0.4548 CNY est (-1.8%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E 17.41.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 600750.SS next report earnings?

Next earnings date2026-08-22
Consensus EPS estimate0.3815 CNY
Revenue estimate0.91B

600750.SS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-240.4466 CNY0.4548 CNY-1.8%Miss
2026-01-230.37 CNY0.3658 CNY+1.1%Beat
2025-10-240.2568 CNY0.2588 CNY-0.8%Miss
2025-04-250.45 CNY0.42 CNY+7.1%Beat
2025-01-240.24 CNY0.24 CNY0%Beat
2024-10-250.23 CNY0.23 CNY0%Beat
2024-08-210.35 CNY0.36 CNY-2.8%Miss

Beat rate: 4/7 (57%) over reported quarters with consensus data.

600750.SS valuation and analyst view

Trailing P/E17.41
Trailing EPS1.446 CNY
Price / book3.68
Dividend yield5.47%
Market cap16.02B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is China Resources Jiangzhong Pharmaceutical (600750.SS)'s next earnings date?

China Resources Jiangzhong Pharmaceutical is next scheduled to report on 2026-08-22, with a consensus EPS estimate of 0.3815 CNY and revenue estimate of 0.91B.

Did 600750.SS beat earnings last quarter?

In its 2026-04-24 report, 600750.SS posted EPS of 0.4466 CNY versus a 0.4548 CNY estimate — a miss of 1.8%.

What is 600750.SS's earnings track record?

Over the last 7 reported quarters with consensus data, 600750.SS beat estimates 4 times (57%).

What is 600750.SS's current P/E ratio and EPS?

600750.SS trades at a trailing P/E of 17.41 on trailing EPS of 1.4456544825749214 CNY.

What do analysts rate 600750.SS?

600750.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.